Early De-escalation of Empirical Antibiotics Treatment for Neutropenic Fever

Recruiting N/A Interventional Study
Safety Issues
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 65
Sex
Any
Study type
Interventional
Purpose
Treatment
Participants needed
200 (estimated)
Sponsor
Shanghai Jiao Tong University School of Medicine · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
This is a randomized study to evaluate the safety and feasibility of early de-escalation of empirical antibiotics treatment in neutropenic fever patients undergoing hematopoietic stem cell transplantation (HSCT). In case of afebrile for 72 hours with empirical antibiotics treatment, patients will be randomized into 2 groups. In the early de-escalation group, antibiotics treatment will be stopped a…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Age ≥18,patients undergo hematopoietic stem cells * Patients with neutropenic fever: T≥38.5°C once or T≥38°C twice a day with ANC \<0.5x109/L or predicted to be \<0.5x109/L in 24 \~48 hours; * Patients achieved afebrile (T\<37.5°C)for at least 72 hours; * Inform consent given …
Contacts

Ling Wang

86-21-64370045

cclingjar@163.com

CONTACT

Jiong HU

86-21-64370045

hj10709@rjh.com.cn

CONTACT